Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner
✍ Scribed by Hüseyin Özyurt; Zeki Yıldırım; Mahir Kotuk; H. Ramazan Yılmaz; Murat Yağmurca; Mustafa Iraz; Sad Söğüt; Serdar Gergerlioglu
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 360 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0260-437X
- DOI
- 10.1002/jat.983
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin‐induced nephrotoxicity. Three different doses of erdosteine at 25, 50 and 75 mg kg^−1^ were studied in rats. Intraperitoneal administration of 7 mg kg^−1^ cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased significantly from 15.1 ± 4.3 to 126.7 ± 152.6 mg dl^−1^ and plasma creatinine levels increased from 0.37 ± 0.005 to 1.68 ± 1.9 mg dl^−1^. When the rats were administered 50 and 75 mg kg^−1^ erdosteine 24 h before cisplatin injection that was continued until sacrifice (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg^−1^ ameliorates cisplatin‐induced renal failure. The optimum dose of erdosteine may be 50 mg kg^−1^ in this study. Copyright © 2004 John Wiley & Sons, Ltd.